I am fully committed to supporting our population screening programmes, which are a valuable part of our health service, enabling early treatment and care for many people, and improving the overall health of our population. The current Programme for Government also commits to further extend the BreastCheck programme.
BreastCheck, the National Breast Screening Programme, currently invites women aged 50 to 69 years at regular periods to have a mammogram. I would highlight that any decisions about further changes in cancer screening, including further extension of the age ranges, will be made on the advice of the National Screening Advisory Committee (NSAC). This independent expert group considers and assesses evidence in a robust and transparent manner, and against internationally accepted criteria. It is important that we have rigorous processes in place to ensure our screening programmes are effective, quality assured and operating to safe standards, and that the benefits of screening outweigh the harms.
In this regard, I am pleased to report that NSAC is already progressing work to consider the further expansion of our cancer screening programmes and has submitted a request to the Health Information and Quality Authority (HIQA) to consider the evidence for a further expansion of the age range eligibility for the BreastCheck programme.
HIQA is currently focused on two Health Technology Assessment (HTA) processes underway to examine the expansion of the BowelScreen programme and the potential development of a population-based screening programme for Abdominal Aortic Aneurism (AAA). Work has already commenced in this regard and reports are expected to be submitted to NSAC for consideration later this year. The evidence review for the expansion of the BreastCheck programme remains a key priority for NSAC and is expected to commence once the ongoing HTAs have concluded.
HTAs facilitate the assessment of relevant evidence and knowledge on the effects and consequences of healthcare technologies to guide decisions regarding the appropriate use of technology and efficient allocation of resources. They involve a multi-disciplinary assessment of the clinical, economic, ethical, legal and societal perspectives that may be impacted by the introduction of a new technology. They are time intensive and rigorous processes.
It is important to emphasise that significant investment continues in our national screening programmes. This includes the allocation of an additional €2.9 million in full-year costs to BreastCheck for 2025. This funding will help to future-proof the programme, allowing for increased capacity and enabling service developments to meet women's evolving needs and ensure equitable access across the entire population.
In terms of your additional queries relating to screening time backlogs, these are a service matter and have been referred to the Health Service Executive for attention and direct reply to you.
Finally, I would like to emphasise that population-based screening programmes are for people without symptoms. If anyone becomes aware of symptoms, or if they have concerns or worries, they should contact their medical professional.